Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Introduction: There is increasing interest in the potential for psychedelic drugs such as
psilocybin, LSD and ketamine to treat several mental health disorders, with a growing …

Background Ketamine appears to have a therapeutic role in certain mental disorders, most
notably depression. However, the comparative performance of different formulations of …

Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA
receptor antagonist, to induce rapid (within hours), transient antidepressant effects when …

This is the first systematic review of the safety of ketamine in the treatment of depression
after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and …

Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

Depression is a well-known serious mental illness, and the onset of treatment using
traditional antidepressants is frequently delayed by several weeks. Moreover, numerous …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …